Teva Pharmaceutical (TEVA) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

Teva Pharmaceutical (TEVA)

34.43

+1.60 (4.87%)

as of Jun 4, 2026, 8:00:00 pm Market Open.

69 watching

Investor Insights

Jun 4, 2026, 12:00 am

This summary was created by AI, based on 2 opinions in the last 12 months.

Teva Pharmaceutical, traded under the symbol TEVA-N, has shown significant improvement, gaining 264% since the new CEO took office in January 2023, suggesting a robust turnaround for the company. After experiencing a rough period post-2002, recent positive financial results indicate that the company's performance is on the upswing. The headquarters in Israel underline its position as a large-cap player in the pharmaceutical industry. Under the current market conditions, Teva is ranked #1 in its ADR/CDR universe, benefiting from a rotation towards drug stocks. Its stock broke through the $21 barrier in September, continuing its upward trend with strong accumulation for the past six months, despite not currently offering a dividend. Analysts are optimistic about its prospects, projecting a price target of $34.50.

Consensus

Positive

Valuation

Undervalued

Similar

Pfeizer, PFE

TOP PICK

Likes the generic space. Expects there will be increasing appetite for governments globally to spend less on health care. Have some very aggressive growth targets for the next 4-5 years. Have been very good at doing acquisitions.

PAST TOP PICK

(A Top Pick May 6/09. Up 37% excluding dividends.) Largest global generic manufacturer. Made acquisitions that strengthens them geographically. Trend towards generics is going to continue.

TOP PICK

Largest manufacturer of generic drugs. Have a pipeline potential of over $100 billion over the next 5 years as patents come off from large pharmaceuticals. Seriously undervalued.

DON'T BUY

Half business is generic drugs. US health care companies are reporting. New US reform will cause increased rebates to Medicaid. This is primary reason for TEVA coming off along with the group.

COMMENT

Generics continue to get wins in terms of shortened time frames as to pharmaceuticals staying on patents.

PAST TOP PICK

(A Top Pick Jan 28/09. Up 34.77%.) Buy on weakness.

TOP PICK

Dominant generics player globally. Has 25% of the generic market in the US. Expecting some form of health care will pass in the US, which will bring 20-40 million people into the health-care system. Trading at only about 15X earnings. Very strong growth prospects.

PAST TOP PICK

(A Top Pick Nov 11/08. Up 24.69%.) Still likes.

BUY

More and more major drugs are coming off patent over the next few years. Being the biggest they will get the lion’s share.

TOP PICK

(A Top Pick May 11/09. Up 12.75%.) Has been in a great uptrend for many years. Thinks you will be able to buy this on a pullback within the next 30 days or so. Fundamentals are good on this company.

PAST TOP PICK

(A Top Pick Oct 14/08. Up 23.38%.) World's largest generic drug company. Also have some branded drugs that are doing very well.

COMMENT

Hasn't added this to portfolios because he is a little bit wary about the generic drug construct in the market and the possibility of the patent drug makers to move into that space. He wouldn't hesitate to have anybody look closely at this one however. Might be slightly overpriced. (See Top Picks.)

BUY

World's largest manufacturer of generic drugs. Also has its own patented proprietary drugs. Has grown through acquisitions and by taking advantage of the drugs that are coming off patent.

COMMENT

Likes the generic drug space, especially with the new US administration. There are a lot of moves up in estimates, both quarterly and annual. He also likes Mylan (MYL-Q), which has a little bit more growth and probably cheaper on a PE level.

DON'T BUY

Once generic stocks have their products in place they can milk it for several years to come. He wouldn't be looking at this right now.

Showing 181 to 195 of 274 entries

Most Recent Experts

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Darren Sissons

Campbell Lee & Ross

The Weekly Buzzing Stocks by Billy Kawasaki

Stockchase

Joe Terranova

Virtus Investment Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Teva Pharmaceutical (TEVA)